Bausch & Lomb Corp

BLCO

Company Profile

  • Business description

    Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

  • Contact

    520 Applewood Crescent
    VaughanONL4K 4B4
    CAN

    T: +1 905 695-7700

    https://www.bausch.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Instruments & Supplies

    Fiscal Year End

    31 December 2026

    Employees

    13,500

Stocks News & Analysis

stocks

What to expect from the January Fed meeting

Central bankers are likely to hold interest rates steady, but Wall Street is focused on life after Powell.
stocks

Fortescue costs outpace increasing volume

Higher diesel prices and foreign exchange hit unit cash costs.
stocks

A top global stock to buy after a big change in its forecast

Undervalued by 24%, this wide-moat stock is a buy now.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,268.5010.000.11%
CAC 408,147.4216.270.20%
DAX 4024,874.6358.45-0.23%
Dow JONES (US)48,923.12489.28-0.99%
FTSE 10010,195.0446.190.46%
HKSE27,126.95361.431.35%
NASDAQ23,806.23204.870.87%
Nikkei 22553,333.54448.290.85%
NZX 50 Index13,510.8850.140.37%
S&P 5006,975.5325.300.36%
S&P/ASX 2008,941.6014.900.17%
SSE Composite Index4,139.907.300.18%

Market Movers